Cobenfy 125 mg/1 (Xanomeline and Trospium Chloride CAPSULE, COATED PELLETS) 125 mg/1

Cobenfy 125 mg/1 combines xanomeline and trospium chloride in coated pellets for oral use. This medication is designed to address specific therapeutic needs, offering a balanced approach to symptom management.

Strength

125 mg/1

Pack Size

60 CAPSULE, COATED PELLETS in 1 BOTTLE (0003-0125-60)

Manufacturer / TM Owner

E.R. Squibb & Sons, L.L.C.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Cobenfy 125 mg/1 is primarily used to manage symptoms associated with certain neurological and urological conditions. The combination of xanomeline and trospium chloride targets specific receptors to provide relief. Users often seek this medication to address what Cobenfy is used for, including discomfort and related symptoms.

Side Effects

Common effects of Cobenfy 125 mg/1 may include mild gastrointestinal discomfort, dry mouth, and dizziness. These effects are generally temporary and may vary among individuals. It's important to monitor how your body responds to this medication.

Precautions & Warnings

Handle Cobenfy 125 mg/1 with care, storing it in a cool, dry place away from direct sunlight. Always follow the instructions provided by your healthcare professional. Avoid sudden changes in dosage without consulting a medical expert.

Avoid Interactions

Cobenfy 125 mg/1 may interact with certain medications, including those that affect the central nervous system or have anticholinergic properties. Alcohol and other depressants should be avoided to prevent potential adverse effects. Always inform your healthcare provider about all medications you are taking.

Frequently Asked Questions

Cobenfy 125 mg/1 is used to manage symptoms associated with certain neurological and urological conditions.

Cobenfy 125 mg/1 should be taken orally, following the instructions provided by your healthcare professional.

Common side effects may include mild gastrointestinal discomfort, dry mouth, and dizziness.

It is generally advised to avoid alcohol while taking Cobenfy 125 mg/1 to prevent potential adverse effects.

Store Cobenfy 125 mg/1 in a cool, dry place away from direct sunlight.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.